Objective: Women undergoing premenopausal oophorectomy for a variety of reasons, including to reduce ovarian or breast cancer risk were evaluated for accelerated bone loss.
W omen undergo oophorectomy for a variety of reasons, including clinical indications such as increased risk of breast and ovarian cancer related to genetic mutations such as BRCA 1/2 mutations or other conditions. [1] [2] [3] [4] Those women who are premenopausal at the time of oophorectomy experience immediate, surgically induced, menopause and are at increased risk of bone loss associated with premature loss of estrogen, and thus increased risk of osteoporosis. 1, [5] [6] [7] Osteoporosis is a disease characterized by low bone mineral density (BMD) 8, 9 and, worldwide, is responsible for more than nine million fractures each year and associated with increased mortality. 8, 10 The rate of bone loss among untreated postmenopausal women causes a doubling in the risk of fracture every 10 years, on average. In addition, agerelated factors other than bone loss also contribute, causing fracture risk to double approximately every 5 years overall. 11 Thus, among women who experience surgically induced menopause, postoophorectomy, the risk is significantly increased for osteoporosis, fracture, as well as for subsequent morbidity and mortality. 12, 13 These studies were, however, conducted among women who underwent natural menopause. [11] [12] [13] There is limited evidence from longitudinal studies to describe the rate of decline in BMD among younger women after oophorectomy.
Few prospective studies have been conducted in a population of women at high risk for ovarian cancer who undergo premenopausal oophorectomy. Studies, however, demonstrate that, among women from the general population who experience surgically induced menopause, the rate of bone loss was accelerated and the risk of osteoporosis was significantly higher. 1, [14] [15] [16] The use of hormonal therapy (HT) is a strategy that will help maintain bone density after menopause, and there are data to show that HT in women experiencing premature menopause (up to mean age of menopause) can help prevent the devastating effects of estrogen deficiency (such as osteoporosis and cardiovascular disease). 17 If there are specific populations of concern, such as women with a history of estrogen-receptor positive cancers, a consultation with a menopause expert should be considered to discuss the specific and individualized risk-benefit ratio. 2, 18 Thus, the current study was designed to test one such strategy for the prevention of bone loss after oophorectomy.
Prompted by our experience with premenopausal oophorectomy among high-risk women in the Gynecologic Oncology Group (GOG)-0199, the National Ovarian Cancer Prevention and Early Detection Trial, 19 the GOG-initiated protocol GOG-0215 to study the impact of an intravenous bisphosphonate (zoledronic acid) on bone loss in premenopausal women at high risk of ovarian cancer who elected to undergo risk reducing oophorectomy (RRO). The rationale for this study was based upon the knowledge that bisphosphonates are effective inhibitors of osteoclastic bone resorption, 20, 21 the recognition that compliance with long-term oral therapy is poor, 22, 23 and data from other studies of zoledronic acid that showed efficacy against risk of facture in other noncancer populations. 24 Unfortunately, GOG-0215 was closed prematurely due to slow accrual and follow-up. Participants enrolled to the control arm of this study, however, (observation only) provided important longitudinal data on post-RRO bone density that may serve to fill an important gap in current knowledge. Therefore, this exploratory study was conducted to measure the patterns and magnitude of bone loss following surgically induced menopause. The results may be useful in the design of future trials and for the counseling of women considering prophylactic oophorectomy by providing additional knowledge about the rate of bone loss among women experiencing surgically induced menopause during the first 18 months after surgery.
METHODS

Study design
The GOG (now a component of NRG) is a National Cancer Institute's cooperative cancer research group, which focuses on cancers of the gynecologic tract. GOG-0215 [NCT-00305695] was designed as a phase-II trial, in which premenopausal women who were planning to undergo RRO were randomized to either observation or to receive three intravenous 4 mg doses of zoledronic acid at 3, 9, and 15 months postsurgery. Women at increased genetic risk of ovarian cancer were eligible for participation, but genetic-risk status was not a requirement and was not evaluated. It was hypothesized that the average decrease in BMD after oophorectomy in premenopausal women would be about 2% during the first year and about 1% per year thereafter. 13 The study was conducted at 40 sites across the United States from November 2005 to April 2010. The GOG-0215 was approved by the respective institutional review boards at each participating site before study activation at that study site.
Exclusion criteria
Eligible participants included premenopausal women who had already elected to undergo RRO or who had already undergone RRO (within 8 wk). Eligible participants also were required to have normal renal function, a baseline BMD Tscore of no less than À1.5 on both the lumbar spine and bilateral hip, and were required to have provided written informed consent before enrollment. Participants were ineligible if they had an existing fracture of the lumbar spine or bilateral hip, or a history of fracture of the hip or spine with or without trauma. Participants with a history of osteoporosis or other diseases that affect bone metabolism (eg, Paget's disease, osteogenesis imperfecta), and participants with uncontrolled thyroid or parathyroid dysfunction, infections, type 2 diabetes, or any other uncontrolled cardiovascular, renal, hepatic, or lung diseases, and patients positive for HIV were also excluded from study participation. Prior bisphosphonate use, endocrine therapy, corticosteroid use, anabolic steroid or growth hormone use, systemic sodium fluoride, tibolone, HT, or any other agents known to affect bone (eg, calcitonin, mithramycin, selective estrogen receptor modulators, aromatase inhibitors) also resulted in the patient being ineligible for study entry. Because of the possible risks in the zoledronic acid treatment group, women were not eligible if they were pregnant, had active dental problems, or had either a recent or planned dental or jaw surgery, including tooth extraction or dental implants.
Treatment and BMD measurement
For the purposes of the current analysis of GOG-0215, only those randomized to the observation arm were included. Participants were instructed to take 1200 mg of calcium supplements and a multivitamin tablet containing 400 to 800 IU of vitamin D once daily. Participants were required to undergo a dual-energy x-ray absorptiometry (DEXA) BMD BONE LOSS AFTER OOPHORECTOMY IN YOUNG WOMEN scan of L1-L4 and the bilateral hip at baseline and 3, 9, 15, and 18 months postoophorectomy. Bone density was measured by T-score and z score at each follow-up time point. Although not used to formally measure osteopenia or osteoporosis, the z score data are an indication of bone loss relative to women of the same age. Traditionally, however, osteopenia is considered when bone density is more than 0.648 g/cm 2 and at most 0.833 g/cm 2 , whereas osteoporosis is defined as BMD less than 0.648 g/cm 2 . 25 Participants were enrolled at 40 study sites, each of which used its own DEXA scan equipment and institutional imaging protocols for the study.
Statistical considerations
Participant characteristics and demographics at baseline were evaluated by means (observed range) and frequencies.
The change in bone density was calculated for each patient from baseline to each follow-up time point, and presented both in terms of g/m 2 and as a standardized z score. The average change at each time point was evaluated. Owing to a relatively small sample size and issues with study adherence, only trends in these data were evaluated. No statistical tests were used to evaluate differences by anatomical location or time points.
RESULTS
The GOG-0215 study was activated for enrollment in November, 2005 and enrolled participants until it was closed to further accrual in April, 2010, having reached only approximately 70% of the planned accrual goals after more than 4 years of enrollment. A total of 160 participants were enrolled, 80 of whom were randomized to observation only. The demographic characteristics of observation arm participants are presented in Table 1 . The majority of women were between 40 to 49 years (60%), whereas 30% were between 30 to 39 years age. Only a single participant (1.3%) was younger than 30 years, and seven (8.8%) were older than 50 years age. The large majority of participants in the observation arm were white (90.0%) and non-Hispanic (78.8%), whereas 8.7% and 12.5% reported African American race and Hispanic ethnicity, respectively.
Protocol adherence
Participant adherence to the study protocol for DEXA BMD scans is presented in Table 2 . Fifty-three (66.2%) of 80 participants in the observation group completed all three DEXA scans. In comparison, only 48% of the treatment arm participants were adherent to bone density scans as required by the study protocol (data not shown). Of eligible observation arm participants, 78 (97.5%), 68 (85.0%), and 55 (68.8%) underwent a DEXA scan and provided bone density data available at the baseline, 9-month, and 18-month time points, respectively. As Table 2 also demonstrates, approximately one-third of participants, 27 (33.8%), however, missed at least one DEXA scan.
BMD
The trends in BMD (mean and range) over time are presented in Table 3 . Overall, we observed a trend of decreasing BMD over 18 months in the observation-only group at all body sites evaluated. For the lumbar spine, the mean baseline BMD was 1.18 g/cm 2 (range ¼ 0.82-1.59); by the 18-month visit, the mean BMD declined to 1.08 g/cm 2 (range ¼ 0.81-1.45). Measures from the right and left hips followed a similar declining pattern. The percent change in BMD after 18 months was À8.5% for the lumbar spine and À5.7% for both the right and left hip. Overall, the average mean changes over the study period were À0.09 (95% CI, À0.12 to À0.07), À0.05 (95% CI, À0.07 to À0.03), and À0.06 (95% CI, À0.07 to À0.05) g/cm 2 across the lumbar spine, right hip, and left hip, respectively. At all three measurement sites, the z scores demonstrated similar trends. The mean change in z score over the study period was À0.69 (95% CI, À0.84 to À0.54) g/cm 2 in the lumbar spine compared with À0.34 (95% CI, À0.48 to À0.19) and À0.35 (95% CI, À0.44 to À0.26) in the right and left hips, respectively.
DISCUSSION
The GOG-0215 phase II, randomized trial demonstrated bone loss in the lumbar spine and hips after risk-reducing oophorectomy. We observed a decrease in BMD at the lumbar spine and both hips (À8.5% and À5.7%, respectively) after 18 months. Correspondingly, we observed a mean decrease in BMD at the same sites from baseline to 18 months (À0.09, À0.05, and À0.06 g/cm 2 across the lumbar spine, left hip, and right hip, respectively). These losses occurred despite supplementation with 1200 mg of calcium and 400 to 800 IU vitamin D per day, which meet the current Institute of Medicine recommendations for intake. 26 Parenthetically, it is worth noting that the data supporting the value of calcium/vitamin D supplements in mitigating the risk of osteoporosis-related fracture are much weaker than are commonly understood, evidence that underscores the need for more effective therapeutic options. 27, 28 Although this trial was stopped early due to slow accrual, our results from the control arm provide important evidence from a randomized clinical trial setting documenting the rapidity with which bone loss occurs immediately after oophorectomy. Additional randomized trials will be required to evaluate lifestyle and novel pharmacologic treatments for bone loss in this high-risk population of women. Previous general population studies have shown that premature menopause due to oophorectomy is associated with an increased risk of osteoporosis, 29,30 a disease characterized by low BMD, enhanced bone fragility, and increased susceptibility to fracture. 9, 31 Furthermore, additional studies have demonstrated that the rate of bone loss is accelerated in the first year postoophorectomy. 32, 33 For example, Hashimoto et al 33 studied 244 women postoophorectomy for more than 10 years and reported that BMD loss was 10.7%, 5.7%, and 1.1% in the first, second, and subsequent years, respectively. In a longitudinal study, Yoshida et al 16 When planning the current study, it was estimated that the decrease in BMD in premenopausal women would be approximately 2% during the first year after oophorectomy and about 1% per year thereafter. The results of GOG-0215 demonstrated that women lost almost 9% BMD from the lumbar spine and 6% in each hip. In a cross-sectional study of BRCA carriers, 71% of women younger than 50 years of age who had undergone oophorectomy were diagnosed by DEXA with either osteopenia (57%) or osteoporosis (14%), particularly in the absence of HT. 3 Garcia et al 5 also recently reported that among 225 BRCA1/2 carriers, studied for a median of 41 months postoophorectomy, nearly a third had normal DEXA scan results, whereas 55.6% showed osteopenia and 12.1% osteoporosis. Additional recent studies among BRCA carriers identified similar trends of lower BMD after oophorectomy. 7, 6 In contrast, a recent study by Fakkert et al 34 found that BMD was not significantly lower among premenopausal women (n ¼ 212) 5 years postoophorectomy compared with the general population data, although BRCA status was not considered. In the current study, few participants fell below the threshold for osteopenia; however, BRCA status was unknown and significant study-related noncompliance may also have influenced these results.
The results of GOG-0215, similar to existing literature, demonstrate a rapid, short-term decline in BMD over time induced by early menopause and thus increased risk of osteoporosis. Strategies such as lifestyle interventions to increase physical activity 1, 35 or different medications such as zoledronic acid or denosumab 36, 37 should continue to be explored in large, long-term trials. It is estimated that 600,000 US women undergo hysterectomy per year for any reason, and that 50% of these procedures include removal of the ovaries, with a peak rate of concomitant oophorectomy occurring among women under age 54. 38 These women may also face the increased risk of osteoporosis and fracture associated with surgically induced menopause, in combination with the normally occurring risk with increasing age and other established risk factors such as smoking, physical inactivity, and BMD, bone mineral density; DEXA, dual-energy x-ray absorptiometry. a A total of n ¼ 6 participants were missing a scan at one anatomical site (n ¼ 3 participants missing lumbar spine scans, n ¼ 2 missing right hip scans, and n ¼ 1 missing left hip scan).
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overweight. Thus, it is critical to continue to study this growing population of high-risk women and evaluate alternative interventions to reduce the risk of bone disease. The strengths of GOG-0215 include its randomized design and prospective follow-up of high-risk participants. Furthermore, BMD was measured at multiple time points and three anatomical locations. Limitations include the challenges faced in both study recruitment and protocol compliance, which resulted in early study closure. In addition, the prospective follow-up was limited to only 18 months, as the original design of the study was intended to demonstrate a difference in the rate of bone loss between treated and untreated participants.
CONCLUSIONS
This study demonstrates a decline in BMD, at three anatomical locations, among women who have undergone surgically induced menopause after an oophorectomy. Future randomized studies in large populations with longitudinal measurement should be conducted to test alternative treatments for postoophorectomy osteoporosis.
